ZCG-Backed VENU+ Expands Global Footprint Through Strategic Partnership with Merlin Entertainments
27.5.2026 12:00:00 CEST | Business Wire | Press Release
VENU+, a leading global provider of tech-enabled guest mobility, storage, and entertainment solutions and a portfolio company of Z Capital Group (“ZCG”), today announced a strategic partnership with Merlin Entertainments, a global leader in branded entertainment destinations, to enhance and expand photo capture experiences across Merlin’s international portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527425123/en/
The partnership includes the rollout of VENU+’s Photo Capture platform across 13 Merlin attractions, including flagship destinations such as LEGOLAND® Resorts and the London Eye, spanning Europe, North America, and Asia. The staged implementation is already underway, with several locations operational and additional sites scheduled for activation throughout 2026.
The agreement represents a significant expansion of VENU+’s presence in Europe and marks one of the largest photo capture partnerships in the region to date. It builds on a longstanding relationship between the two companies, with Merlin having partnered with VENU+ across multiple product lines for more than two decades.
Through the partnership, VENU+ will deliver a fully integrated suite of photo capture solutions, including ride photography, immersive media experiences, roaming photography, and digital engagement tools, designed to enhance the guest journey and create lasting, shareable memories.
“We are excited to expand our partnership with Merlin Entertainments and bring our industry-leading photo capture capabilities to some of the world’s most iconic attractions,” said John Dunlap, Chief Executive Officer of VENU+. “This partnership reflects our shared commitment to enhancing the guest experience by creating more opportunities for visitors to capture and relive meaningful moments. As demand for immersive and personalized experiences continues to grow, we are well positioned to deliver innovative solutions at scale.”
The partnership responds directly to increasing guest demand for more dynamic and accessible ways to capture and engage with their experiences. By integrating advanced technologies such as facial recognition, digital content delivery, and real-time media experiences, VENU+ enables attractions to seamlessly blend physical and digital engagement across the guest journey.
“We are delighted to be working in partnership with VENU+ to capture the moments and memories that mean so much to our guests,” said Hywel Mathias, SVP Global Performance at Merlin Entertainments. “Photography is an important part of the experience we offer, and having a partner like VENU+ ensures we can bring families closer through play, and remember their visits long after they leave.”
“At ZCG, we are focused on supporting platforms that enhance the customer experience through innovation and scale,” said James Zenni, Founder, President, and Chief Executive Officer of ZCG. “This partnership highlights VENU+’s ability to execute on large-scale, global opportunities and reinforces its position as a leading provider of technology-enabled solutions for the attractions industry. We are excited to support the team as they continue to expand their global footprint.”
The partnership also signals continued momentum for VENU+’s global growth strategy, with additional product integrations and guest experience enhancements expected across Merlin’s portfolio in the coming years.
About VENU+
VENU+ is the world’s leading provider of full-service, tech-enabled solutions that generate revenue and improve the guest experience for entertainment destinations worldwide. Its offerings include guest mobility, smart lockers, souvenir coins, photo capture, and entertainment solutions. VENU+ operates in all 50 U.S. states and across 13 countries on four continents, setting the global standard for world-class products and services for more than 42 years.
VENU+ is backed by ZCG Private Equity, the private equity arm of Z Capital Group, LLC (“ZCG”), a leading, privately held global firm.
About Merlin
Merlin Entertainments is a world leader in branded entertainment destinations, offering a diverse portfolio of resort theme parks, city-centre gateway attractions and LEGOLAND Resorts which span across the UK, US, Western Europe, China and Asia Pacific. Dedicated to creating experiences that inspire joy and connection, Merlin welcomes more than 60 million guests annually to its diverse global estate in over 20 countries. An expert in bringing world-famous entertainment brands to life, Merlin works with partners including the LEGO Group, Sony Pictures Entertainment, Peppa Pig, DreamWorks and Ferrari to create destinations where guests can immerse themselves in a wide array of brand-driven worlds, rides and uplifting learning experiences. See www.merlinentertainments.biz for more information.
About ZCG
ZCG is a leading, privately held global firm comprised of private markets asset management, business consulting services, and technology development and solutions. ZCG’s investors include pension funds, endowments, foundations, sovereign wealth funds, central banks, and insurance companies. For almost 30 years, ZCG Principals have invested tens of billions of dollars of capital. ZCG has approximately 400 professionals across five countries and is headquartered in New York. For more information, visit www.zcg.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260527425123/en/
Contacts
ZCG Media & Communications
Tel. 212-595-8400
zcgmedia@zcg.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom